ADA and myeloid sarcoma: Anti-drug antibodies (ADA) to rituximab have been reported in 4–11% of patients undergoing treatment for RA [1] and in 26–37% of those receiving treatment for multiple sclerosis (MS), where they associate with impaired B-cell depletion and variable clinical response [2].